Shangpin home delivery and Shulan signed a strategic cooperation agreement. According to Shangpin home delivery, on December 11th, Shangpin home delivery and Shulan formally signed a strategic cooperation agreement at Changshun Group headquarters. The two sides will break through the customized track, explore the path of "customization+software" integration and co-construction, jointly explore market channels, and provide consumers with more convenient, personalized and professional home solutions through integrated and integrated ecological scenarios.The turnover of Shanghai and Shenzhen stock markets exceeded 500 billion.Real estate stocks fluctuated lower, with Gorgeous Family, Qixia Construction, Everbright Jiabao and Tiandiyuan falling more than 5%, while urban construction development and Chongqing development followed suit.
Musk moved SpaceX headquarters to the Starbase in Texas.The three major stock indexes opened lower and went lower. The Shenzhen Stock Exchange Index and the Growth Enterprise Market Index all fell more than 1%, and the Shanghai Composite Index fell 0.88%.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.
Xray, an important partner of Yizhizhuang, officially announced a strategic cooperation with Google. According to Yizhizhuang, at the Android XR conference held in new york, Google officially announced a strategic cooperation with Xray to jointly build the Android XR ecosystem. This cooperation not only highlights XREAL's position as the world's largest manufacturer of AR glasses, but also marks a new stage of accelerated popularization of XR industry. It is noteworthy that Lingyizhi, as a long-term strategic partner of XREAL, provides key components and assembly services for XREAL AR glasses.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Lianxiang Co., Ltd. and others set up a new digital technology company. The enterprise search APP shows that recently, Zhejiang Lianxi Digital Technology Co., Ltd. was established, with Li Xiaoliang as the legal representative and a registered capital of 10 million yuan. Its business scope includes: the first type of value-added telecommunications services; The second kind of value-added telecommunications services, etc. Enterprise investigation shows that the company is jointly held by Lianxiang and others.
Strategy guide
12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide
12-13